Assetmark, Inc Alkermes Plc. Transaction History

Assetmark, Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	BUY	$27.17 - $31.97 $163 - $191	6 New	6 $0
Q1 2019 May 14, 2019	SELL	$28.4 - $36.49 $511 - $656	-18 Closed	0 $0
Q4 2018 Feb 13, 2019	SELL	$27.94 - $44.61 $3,213 - $5,130	-115 Reduced 86.47%	18 $1,000
Q3 2018 Nov 13, 2018	SELL	$38.6 - $46.12 $193 - $230	-5 Reduced 3.62%	133 $6,000
Q2 2018 Aug 01, 2018	BUY	$40.56 - $51.36 $567 - $719	14 Added 11.29%	138 $6,000
Q1 2018 May 16, 2018	BUY	$53.61 - $67.26 $2,251 - $2,824	42 Added 51.22%	124 $7,000
Q4 2017 Feb 13, 2018	SELL	$47.69 - $55.39 $47 - $55	-1 Reduced 1.2%	82 $4,000
Q3 2017 Nov 08, 2017	SELL	$49.16 - $54.45 $49 - $54	-1 Reduced 1.19%	83 $4,000
Q1 2017 Sep 15, 2017	BUY	N/A	2 Added 2.44%	84 $5,000
Q4 2016 Sep 15, 2017	SELL	N/A	-26 Reduced 24.07%	82 $5,000
Q3 2016 Sep 15, 2017	BUY	N/A	26 Added 31.71%	108 $5,000
Q1 2016 Sep 15, 2017	BUY	N/A	42 Added 105.0%	82 $3,000
Q4 2015 Sep 15, 2017	BUY	N/A	40	40 $3,000

364

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.61B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

Stay updated on Assetmark, Inc with notifications on news.